Pay in 4 interest-free payments of $7.15 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
doi: 10.3389/fnmol.2016.00053
The Therapeutic Goods Administration's (TGA) warning covers the following glucagon-like peptide-1 (GLP-1) receptor agonists, which are used to treat type 2 diabetes and obesity: Semaglutide, sold as Ozempic, Wegovy Tirzepatide, sold as Mounjaro Dulaglutide, sold as Trulicity Liraglutide, sold as Saxenda The TGA said the products had the potential to cause an eye disorder called non-arteritic anterior ischaemic optic neuropathy (NAION)
Creates irreversible structural damage that neither visual inspection nor home testing can detect
No side effect, notice a little more energy on this 1st month dosing
:max_bytes(150000):strip_icc()/GettyImages-1807240274-2c7c39cb23f34a97bb2d8620911c343d.jpg)
US$ 28.00
US$ 23.89
US$ 28.80
US$ 20.77
US$ 20.65
